latanoprost and Pulmonary-Disease--Chronic-Obstructive

latanoprost has been researched along with Pulmonary-Disease--Chronic-Obstructive* in 1 studies

Other Studies

1 other study(ies) available for latanoprost and Pulmonary-Disease--Chronic-Obstructive

Article	Year
[Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD)]. Archivos de la Sociedad Espanola de Oftalmologia, 2002, Volume: 77, Issue:10 To study the respiratory effects of chronic therapy with latanoprost in Chronic Obstructive Pulmonary Disease (COPD) patients.. We prospectively performed a spirometry in 19 COPD patients treated with latanoprost for more than 3 months, and the same masked-examiner repeated the test, under the same conditions, one week after latanoprost wash-out.. We found that latanoprost withdrawal increased forced espiratory volume (FEV1) (litre) from 1.5 S.D. 0.5 to 1.6 S.D. 0.5 and FEV1/FVC (forced vital capacity) index from 64.4 S.D. 8.6% to 66.5 S.D. 7.7% (both comparisons p=0.02, Wilcoxon signed-rank test).. Chronic therapy with latanoprost seems to induce a mild, though statistically significant, bronchoconstriction in COPD patients. Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Humans; Latanoprost; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Pulmonary Disease, Chronic Obstructive; Respiration	2002

Article

Year

[Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD)].

Archivos de la Sociedad Espanola de Oftalmologia, 2002, Volume: 77, Issue:10

To study the respiratory effects of chronic therapy with latanoprost in Chronic Obstructive Pulmonary Disease (COPD) patients.. We prospectively performed a spirometry in 19 COPD patients treated with latanoprost for more than 3 months, and the same masked-examiner repeated the test, under the same conditions, one week after latanoprost wash-out.. We found that latanoprost withdrawal increased forced espiratory volume (FEV1) (litre) from 1.5 S.D. 0.5 to 1.6 S.D. 0.5 and FEV1/FVC (forced vital capacity) index from 64.4 S.D. 8.6% to 66.5 S.D. 7.7% (both comparisons p=0.02, Wilcoxon signed-rank test).. Chronic therapy with latanoprost seems to induce a mild, though statistically significant, bronchoconstriction in COPD patients.

Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Humans; Latanoprost; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Pulmonary Disease, Chronic Obstructive; Respiration

2002